The complement system is a key component of innate and adaptive immunity and therefore acts as a vital defense against invading pathogens. Deficiencies in the complement system are associated with ...

It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...

A component of the complement system promotes tumor growth by activating myeloid-derived suppressor cells. Figure 1: Multiple pro-inflammatory mediators in the tumor microenvironment increase the ...

University of Pennsylvania researchers have found a promising new treatment for periodontitis using a component of the immune system called complement, according to a new study in the Journal of ...

Long Covid patients suffer from chronic symptoms such as fatigue or shortness of breath. As researchers have discovered, this is to some extent due to a part of our immune system called the complement ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...

Researchers in the United States have conducted a study showing that activation of the complement system is specifically implicated in the pathogenesis of severe coronavirus disease 2019 (COVID-19), ...

Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests. For many people, covid is an illness that blusters in and out of our lives as cases ...

In view of the importance of complement system in the initiation, regulation and end effects of immune responses and understanding of immune system as one of the targets for the toxic effects of ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of ...